Abstract
We provide follow-up data on the humoral immune response after COVID-19 vaccinations of a cohort aged below 60 and over 80 years. While anti-SARS-CoV-2 spike-specific IgG and neutralization capacity waned rapidly after initial vaccination, additional boosters highly benefitted humoral immune responses including neutralization of Omikron variants in the elderly cohort.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Stiftung für Altersforschung, Düsseldorf [to H.S., L.W.], Jürgen Manchot foundation [to H.S., I.D. L.M., L.W., A.R., J.T., R.G.], by research funding from Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) grant GK1949/2 and project number 452147069 [to I.D.], by the Ministry of Labour, Health and Social Affairs of North-Rhine Westphalia (CPS-1-1A), by the Federal Ministry of Education and Research (01KX2021) and by the Forschungskommission of the Medical Faculty, Heinrich-Heine-Universität Düsseldorf [to H.S., J.P., J.H.]
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of the Medical Faculty at the Heinrich-Heine University Düsseldorf, Germany (study no. 2021-1287), approved the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
